Last update April 8, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Medroxyprogesterone Acetate is also known as
Medroxyprogesterone Acetate in other languages or writings:
Medroxyprogesterone Acetate belongs to these groups or families:
Main tradenames from several countries containing Medroxyprogesterone Acetate in its composition:
|Oral Bioavail.||oral: < 10||%|
|Protein Binding||86 - 94||%|
|VD||0.2 - 0.4||l/Kg|
|Tmax||oral: 1 - 3; im. Sc: 120 - 144||hours|
|T½||oral: 40-60; im. sc: 480 -1200||hours|
|Theoretical Dose||0.0002 - 0.001||mg/Kg/d|
|Relative Dose||0.7 - 3.6||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Synthetic progestin similar to progesterone that is used in uterine bleeding, dysmenorrhea, infertility and contraception. For contraception is used as a single drug or in combination with estrogen. Daily oral administration or long-acting injection (intramuscular or subcutaneous) every 3 to 6 months.
It is excreted into breast milk in clinically non-significant amount (Koetsawang 1982, Saxena 1977) and no problems have been observed in infants whose mothers who were treated with this medication (Singhal 2014, Díaz 1997, WHO 1994, Pardthaisong 1992, Zacharias 1986, Jiménez 1984, Dahlberg 1982, Karim 1971). Urinary medroxyprogesterone levels of these infants were undetectable. (Virutamasen 1996)
There may be increased prolactin and milk production in women who receive medroxyprogesterone. (Omar 2006, Ratchanon 2000).There is no evidence of its effectiveness as a galactogogue. (Zuppa 2010)
Although it has not been shown effects on production and duration of breastfeeding when administered at any time postpartum (Parker 2021, Phillips 2016, Singata 2016, Singhal 2014, Brownell 2013, Halderman 2002, Danli 2000, Hannon 1997, Karim 1971), it is still controversial on if it really decreases milk production when progestins are used before a fully establishment of breastfeeding has occurred. (Brownell 2012, Rodriguez 2009)
During breastfeeding progestin-only contraceptives are preferable to those combined with estrogen and, in this case, those with a lower dose of estrogen. (CDC 2016, 2013 y 2010, WHO/OMS 2015, Altshuler 2015, Berens 2015, CLM 2012, FFPRHC 2004, Moretti 2000, Guiloff 1974)
For the first 4-6 weeks postpartum, non-hormonal methods are the first choice, followed by IUDs and progestogen implants. (Berens 2015, Mwalwanda 2013, Rowe 2013, CLM 2012, Kaunitz 1998)
American Academy of Pediatrics: medication usually compatible with breastfeeding.(AAP 2001)
WHO List of Essential Medicines 2002: rates it as compatible with breastfeeding after the 6th postnatal week. (WHO 2002)
See below the information of this related product: